An observational study in Neuroblastoma and Ewing Sarcoma, sponsored by University Hospital, Clermont-Ferrand. Recruiting at 1 site in France. Open to participants aged 2 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-09-03.
Sponsored by University Hospital, Clermont-Ferrand · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Neuroblastoma with a site in France — 10 open to participants now, 15 under way, 2 of them phase 3. Neuroblastoma · France.
Among the 54 studies in Neuroblastoma with a site in France, this one is one of 2 that started in 2025, is one of 4 observational ones, reaches primary completion later than 7 of the 14 other live ones, and was the 53rd registered.
676 studies on the registry are indexed under Neuroblastoma; 127 are open to participants now.
Browse Neuroblastoma studies →10 of the 54 studies in Neuroblastoma with a site in France are open now. Recruiting first, the newest first:
Renaissance Pharma Ltd. · Sites in France, United States, Canada and 4 more countries
Ages 18 mo–18 yrs
Merck Sharp & Dohme LLC · Sites in France, United States, Australia and 20 more countries
Ages 6 mo–25 yrs
University Hospital, Strasbourg, France · Sites in France
Ages 2–25
Institut Curie · Sites in France, Czechia, Norway and 1 more country
Gustave Roussy, Cancer Campus, Grand Paris · Sites in France
Ages up to 25
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 104 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 74 (71%) stop at 75 or younger; 101 take children under 18; 3 take healthy volunteers.
This study: 2 Years to 45 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 28 · Phase 3 7 · Phase 4 1
First in 1994; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 89 is below the median of 123 across 84 observational studies indexed under Neuroblastoma.
Median enrollment 102 across the 44 interventional studies, 107 across the 4 observational. Of the 32 that completed or were terminated, 10 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 54 have an industry lead sponsor. The 10 most frequent:
University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 177 are open to participants now.
University Hospital, Clermont-Ferrand has 2 studies filed under Neuroblastoma — fewer than ten, so there is no comparison to draw.
5 of the studies in Neuroblastoma with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04221035Phase 3Gustave Roussy, Cancer Campus, Grand ParisHigh-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) | 2026-11 |
| NCT03975829Novartis PharmaceuticalsPediatric Long-Term Follow-up and Rollover Study | 2026-11-24 |
| NCT03496402Institut CurieBiological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO) | 2027-04-19 |
| NCT02650401Hoffmann-La RocheStudy Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | 2027-06-30 |
| NCT07141862University Hospital, Clermont-FerrandFertility Preservation in Children With Solid Tumors: Detection of Residual Disease by a Sensitive Method | 2027-06-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 54 studies in Neuroblastoma with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In prepubertal patients, cryopreservation of ovarian or testicular tissue is currently the only available method for fertility preservation prior to gonadotoxic cancer treatments. However, this approach carries the risk of reintroducing malignant cells upon autotransplantation, particularly in cases of metastatic cancers such as neuroblastoma and Ewing sarcoma. Therefore, it is crucial to employ highly sensitive techniques to detect minimal residual disease (MRD) in preserved gonadal tissues.
This study aims to identify the most effective detection method by comparing the sensitivity and specificity of reverse transcription quantitative PCR (RT-qPCR) and droplet digital PCR (ddPCR) in identifying MRD of neuroblastoma and Ewing sarcoma in ovarian and testicular tissues from patients treated for these malignancies during infancy.
Ovarian and testicular cryopreservation is the only option to preserve the fertility of children diagnosed with cancer. Cancer treatments such as chemotherapy and radiotherapy can lead to gonadal toxicity. However, there is a risk of reintroducing tumor cells when the germinal tissue is reused. This is known as residual disease. This risk is higher in the case of metastatic cancers such as neuroblastoma and Ewing sarcoma. These two solid tumors are associated with a high risk of relapse and disease progression after treatment. Neuroblastoma is the most common extracranial solid tumor in children. One characteristic of this neuroendocrine tumor is its high frequency of metastatic disease. Several cases of metastasis have been reported in ovarian and testicular tissues.
Regarding Ewing sarcoma, it is the second most common bone cancer in children. Approximately 27% of patients show evidence of metastasis at diagnosis; these circulating tumor cells can reach the germinal tissues.
Several detection methods are available for these two solid tumors, such as histopathological analysis with hematoxylin-eosin staining, and immunohistochemistry targeting cellular markers with fluorescent antibodies. However, the main limitation of these two methods is their low sensitivity for detecting only a few tumor cells. That is why RT-qPCR and ddPCR, which have high detection sensitivity, have been developed. These two molecular methods are currently used for the detection of residual disease in leukemia and lymphoma. However, no studies have investigated the detection of residual disease of neuroblastoma and Ewing sarcoma by ddPCR in ovarian and testicular tissues.
Therefore, the goal of this study is to validate the detection of residual disease of neuroblastoma and Ewing sarcoma by ddPCR in ovarian and testicular tissues. In addition, the second goal is to evaluate the specificity and sensitivity of residual disease detection for these two solid tumors in ovarian and testicular tissues using RT-qPCR and ddPCR.
First, an in vitro model has been developed to mimic the metastatic dissemination of neuroblastoma and Ewing sarcoma in germinal tissues. To do this, two tumor cell lines will be used: IMR-32 for neuroblastoma and RD-ES for Ewing sarcoma. Then, 10 ovarian tissues and 10 testicular tissues will be contaminated with increasing quantities of neuroblastoma tumor cells: 5, 10, 20, and 100 tumor cells. The same procedure will be applied in the case of Ewing sarcoma. Ovarian tissues are derived from women of any age diagnosed with a benign cyst requiring laparoscopy. Testicular tissues are derived from men of any age diagnosed with non-obstructive azoospermia. These ovarian and testicular models have been validated by our team through preliminary work. These models are as close as possible to prepubertal tissues with immature gametes. Next, the investigators will perform RNA extraction with TRIzol reagent, followed by reverse transcription to generate complementary DNA (cDNA) and RT-qPCR and ddPCR to detect the specific tumor genes: PHOX2B for neuroblastoma and EWSR1-FLI1 for Ewing sarcoma.
Residual disease detection will be conducted on ovarian and testicular tissues collected from prepubertal patients diagnosed and treated for neuroblastoma or Ewing sarcoma during infancy. These patients underwent germinal tissue cryopreservation as a fertility preservation strategy following their cancer diagnosis.
Total RNA will be extracted from the cryopreserved tissues using TRIzol reagent. Subsequently, reverse transcription will be performed. The presence or absence of tumor-specific transcripts will be assessed using both reverse transcription quantitative PCR (RT-qPCR) and droplet digital PCR (ddPCR). Specifically, the neuroblastoma-associated PHOX2B gene and the Ewing sarcoma-specific EWSR1-FLI1 fusion transcript will be targeted.
By comparing the sensitivity and specificity of RT-qPCR and ddPCR for detecting minimal residual disease in these tissues, this study aims to determine the most effective and reliable protocol for identifying residual tumor cells. The findings will support the safe future use of cryopreserved ovarian and testicular tissues in fertility restoration for pediatric cancer survivors.
Residual disease detection will be conducted on ovarian and testicular tissues collected from prepubertal patients diagnosed and treated for neuroblastoma or Ewing sarcoma during infancy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
First, the detection of minimal residual disease of neuroblastoma and Ewing sarcoma will be performed on an in vitro model that mimics the metastatic dissemination of these two solid tumors. Ovarian and testicular tissues will be contaminated with increasing quantities of tumor cells (0, 5, 10, 20, and 100 tumor cells) from neuroblastoma (IMR-32) and Ewing sarcoma (RD-ES). Then, the detection of MRD will be carried out on ovarian and testicular tissues from prepubertal patients diagnosed and treated for neuroblastoma and Ewing sarcoma during infancy. To detect this MRD in both models, the investigators will perform RNA extraction using TRIzol reagent, followed by reverse transcription and RT-qPCR to detect the specific tumor genes: PHOX2B for neuroblastoma and EWSR1-FLI1 for Ewing sarcoma.
Diagnostic Test: RT-qPCR
First, the detection of MRD of neuroblastoma and Ewing sarcoma will be performed on an in vitro model that mimics the metastatic dissemination of these two solid tumors. Ovarian and testicular tissues will be contaminated with increasing quantities of tumor cells (0, 5, 10, 20, and 100 tumor cells) from neuroblastoma (IMR-32) and Ewing sarcoma (RD-ES). Then, the detection of MRD will be carried out on ovarian and testicular tissues from prepubertal patients diagnosed and treated for neuroblastoma and Ewing sarcoma during infancy. To detect this MRD in both models, the investigators will perform RNA extraction using TRIzol reagent, followed by reverse transcription and ddPCR to detect the specific tumor genes: PHOX2B for neuroblastoma and EWSR1-FLI1 for Ewing sarcoma.
Diagnostic Test: ddPCR
Detection of MRD of neuroblastoma and Ewing sarcoma in ovarian and testicular tissues using RT-qPCR
Detection of MRD of neuroblastoma and Ewing sarcoma in ovarian and testicular tissues using ddPCR
Validation of residual disease detection of neuroblastoma and Ewing sarcoma by ddPCR in ovarian and testicular tissues.
Detection of the copy number of specific tumor genes: PHOX2B for neuroblastoma and EWSR1-FLI1 for Ewing sarcoma in ovarian and testicular tissues using ddPCR. Residual disease will be detected in ovarian and testicular tissues contaminated with increasing quantities of tumor cells (0, 5, 10, 20, and 100 tumor cells) from neuroblastoma (IMR-32) and Ewing sarcoma (RD-ES), as well as in ovarian and testicular tissues from prepubertal patients diagnosed and treated for neuroblastoma and Ewing sarcoma during infancy.
Time frame: From 02-2025 to 02-2026 for analysis of neuroblastoma; from 02-2026 to 12-2027 for analysis of Ewing sarcoma.
Evaluation of the specificity and sensitivity of RT-qPCR and ddPCR for detecting residual disease of neuroblastoma and Ewing sarcoma in ovarian and testicular tissues.
Detection of the copy number of specific tumor genes: PHOX2B for neuroblastoma and EWSR1-FLI1 for Ewing sarcoma in ovarian and testicular tissues using RT-qPCR and ddPCR. Residual disease will be detected in ovarian and testicular tissues contaminated with increasing quantities of tumor cells (0, 5, 10, 20, and 100 tumor cells) from neuroblastoma (IMR-32) and Ewing sarcoma (RD-ES), as well as in ovarian and testicular tissues from prepubertal patients diagnosed and treated for neuroblastoma and Ewing sarcoma during infancy. The sensitivity and specificity of each detection method will then be compared.
Time frame: From 02-2025 to 02-2026 for analysis of neuroblastoma; from 02-2026 to 12-2027 for analysis of Ewing sarcoma.
Evaluation of the impact of ovarian tissue freezing protocols on RNA Quantity and Purity
Two ovarian tissue freezing protocols will be tested. Half of the ovarian tissues contaminated by neuroblastoma tumor cells (IMR-32) will be frozen and thawed using the protocol describe by Gosden in 1994, and the other half using the protocol developed by Schubert in 2005. RNA quantity and purity, including protein and chemical contamination will be compared between the two protocols. The same analysis will be performed on ovarian tissues contaminated with Ewing sarcoma tumor cells (RD-ES).
Time frame: From 02-2025 to 02-2026 for analysis of neuroblastoma; from 02-2026 to 12-2027 for analysis of Ewing sarcoma
Plan to share: Undecided
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Jun 2027, 28 months after the start.
Of 34 observational studies under Neuroblastoma, half reached primary completion within 213 months of starting (the median), counting those still running; a quarter within 74 and three quarters within 304. This study's planned 28 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Clermont-Ferrand →